Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty
Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” said Vertex’s COO.